ERBB2 and breast cancer: Previous studies analyzed the distribution of HER2-low breast cancer within the HER2-negative population, reporting results ranging from 47.5% to 59.7% (Shui et al., 2020; Denkert et al., 2021; Schettini et al., 2021).